HARP News and Press, Harpoon Therapeutics Inc. From 01/13/21

The FDA has granted Orphan Drug Designation to Harpoon Therapeutics' (HARP) HPN217 for the treatment of multiple myeloma.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.HPN217, a tri-specific T cell activating r...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation ...

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP) announced today the closing of its underwritten public offering of 6,764,704 shares of its common stock, which includes 882,352 shares sold upon the underwriters’ full exercise of...

Harpoon Therapeutics (HARP) has priced its public offering of ~5.9M common shares at $17.00/share, for expected gross proceeds of ~$100M.Underwriters' over-allotment is an additional ~882.4K shares. Net proceeds will be used for the development of pipeline candidates, for working capital and ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share. Harpoon Therapeutics expects that th...

Gainers: [[SOS]] +63.9%. [[XNET]] +23.7%. [[TEN]] +11.2%. [[CERS]] +8.9%. [[SITM]] +8.3%.Losers: [[GBTC]] -8.9%. [[PLYA]] -7.5%. [[UUU]] -6.5%. [[INN]] -6.4%. [[HARP]] -5.8%. For further details see: SOS, XNET, UUU and PLYA among after-hours movers

Harpoon Therapeutics (HARP) commences an underwritten public offering of its common stock.Underwriters option to purchase up to an additional 15% of the number of shares sold.Net proceeds of the offering, together with other available funds, to fund the continued clinical development of ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock. In connect...

Harpoon Therapeutics (HARP) has dosed the first patient with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer ((SCLC)) and other tumors associated with DLL3 expression.The trial plans to enroll pati...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targ...